- Home
- PNRG vs CLLS Comparison
PNRG vs CLLS Comparison
Compare PNRG & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNRG
- CLLS
- Stock Information
- Founded
- PNRG 1973
- CLLS 1999
- Country
- PNRG United States
- CLLS France
- Employees
- PNRG N/A
- CLLS N/A
- Industry
- PNRG Oil & Gas Production
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- PNRG Energy
- CLLS Health Care
- Exchange
- PNRG Nasdaq
- CLLS Nasdaq
- Market Cap
- PNRG 207.8M
- CLLS 240.2M
- IPO Year
- PNRG N/A
- CLLS 2007
- Fundamental
- Price
- PNRG $200.00
- CLLS $1.87
- Analyst Decision
- PNRG
- CLLS Buy
- Analyst Count
- PNRG 0
- CLLS 3
- Target Price
- PNRG N/A
- CLLS $7.00
- AVG Volume (30 Days)
- PNRG 4.6K
- CLLS 93.0K
- Earning Date
- PNRG 11-26-2024
- CLLS 11-04-2024
- Dividend Yield
- PNRG N/A
- CLLS N/A
- EPS Growth
- PNRG 71.12
- CLLS N/A
- EPS
- PNRG 23.14
- CLLS N/A
- Revenue
- PNRG $210,064,000.00
- CLLS $36,042,000.00
- Revenue This Year
- PNRG N/A
- CLLS $271.02
- Revenue Next Year
- PNRG N/A
- CLLS $33.48
- P/E Ratio
- PNRG $8.72
- CLLS N/A
- Revenue Growth
- PNRG 88.03
- CLLS 46.96
- 52 Week Low
- PNRG $92.40
- CLLS $1.70
- 52 Week High
- PNRG $203.03
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- PNRG 71.51
- CLLS 47.58
- Support Level
- PNRG $175.39
- CLLS $1.70
- Resistance Level
- PNRG $188.78
- CLLS $2.00
- Average True Range (ATR)
- PNRG 5.25
- CLLS 0.11
- MACD
- PNRG 1.54
- CLLS 0.02
- Stochastic Oscillator
- PNRG 92.96
- CLLS 56.67
About PNRG PrimeEnergy Resources Corporation
PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and provide well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.